<DOC>
	<DOCNO>NCT00014690</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining two drug may kill tumor cell . PURPOSE : Randomized phase II trial study effectiveness different regimen ZD9331 without topotecan treating patient refractory recurrent epithelial ovarian cancer , fallopian tube cancer primary peritoneal cancer .</brief_summary>
	<brief_title>ZD9331 With Without Topotecan Treating Patients With Refractory Recurrent Epithelial Ovarian Cancer , Fallopian Tube Cancer , Primary Peritoneal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare efficacy ZD9331 without topotecan patient refractory recurrent ovarian epithelial , primary peritoneal , fallopian tube cancer . II . Compare tolerability regimens patient . III . Compare objective tumor response rate , progression-free survival , disease control patient treat regimen . IV . Compare quality life patient treat regimen . OUTLINE : This randomize , open-label , multicenter study . Patients randomize 1 3 treatment arm . Arm I : Patients receive ZD9331 IV 30 minute day 1 8 . Arm II : Patients receive high dose ZD9331 IV 30 minute day 1 8 . Arm III : Patients receive ZD9331 arm I topotecan IV 30 minute day 1-5 . All arm : Treatment repeat every 21 day absence disease progression unacceptable toxicity . Quality life assess baseline , first day course , study withdrawal . Patients follow day 30 , every 9 week disease progression , every 6 month thereafter . PROJECTED ACCRUAL : Approximately 130 patient accrue study within 5 month .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>ZD 9331</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm ovarian epithelial cancer , primary peritoneal cancer , fallopian tube cancer Refractory recurrent disease combination platinum paclitaxel prior chemotherapy regimen Platinum resistant ( i.e. , refractory relapse within 6 month completion last therapy regimen ) No 2 prior platinum paclitaxel combination regimens Measurable disease No CNS metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : WHO 01 Life expectancy : More 12 week Hematopoietic : Neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : No unstable uncompensated hepatic disease Bilirubin le 1.25 time upper limit normal ( ULN ) Albumin least low limit normal ALT AST great 2.5 time ULN ( 5 time ULN liver metastasis present ) Renal : No unstable uncompensated renal disease Creatinine clearance least 60 mL/min Cardiovascular : No unstable uncompensated cardiac disease Pulmonary : No unstable uncompensated respiratory disease Other : No concurrent intestinal obstruction No evidence severe uncontrolled systemic disease No active malignancy within past 5 year except squamous cell basal cell skin cancer carcinoma situ cervix No severe concurrent condition would preclude study compliance No risk transmit HIV hepatitis B C Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : No prior extensive radiotherapy 30 % bone marrow ( e.g. , whole pelvis half spine ) No concurrent radiotherapy ovarian cancer Surgery : At least 2 week since prior surgery , except insertion central venous access device , recover Other : At least 4 week since anticancer therapy recover Concurrent folic acid nutritional supplement allow except within 24 hour ZD9331 dose No concurrent study drug No concurrent systemic therapy ovarian cancer</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2004</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
</DOC>